ArticleWorld journal of urology2017
Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk.
Article in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- AHSP as a novel non-invasive urinary biomarker for prostate cancer.BMC cancer · 2026Article
- Comparison of the prognoses after two different surgical procedures plus radiotherapy in the treatment of patients with prostate cancer: survival analysis based on propensity score matching.International urology and nephrology · 2025Article
- Article
- Artificial intelligence-based personalized clinical decision-making for patients with localized prostate cancer: surgery versus radiotherapy.The oncologist · 2024Article
- Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer.Acta oncologica (Stockholm, Sweden) · 2024Article
- A Pilot Study on Patient-specific Computational Forecasting of Prostate Cancer Growth during Active Surveillance Using an Imaging-informed Biomechanistic Model.Cancer research communications · 2024Article
- Access to cancer clinical trials for racialised older adults: an equity-focused rapid scoping review protocol.BMJ open · 2024Article
- Symptom burden profiles in men with advanced prostate cancer undergoing androgen deprivation therapy.Journal of behavioral medicine · 2022Article
- Article
- Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer - Brachytherapy enhanced late GU toxicity especially in elderly.Clinical and translational radiation oncology · 2020Article
- Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype Determination.Proteomics. Clinical applications · 2020Article
- Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation.BMC medicine · 2020Article
- Decision Aid Implementation and Patients' Preferences for Hip and Knee Osteoarthritis Treatment: Insights from the High Value Healthcare Collaborative.Patient preference and adherence · 2020Article
- A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.World journal of urology · 2019Article
- Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England.International journal of cancer · 2019Article
- Effect of Androgen Deprivation Therapy on Other-Cause of Mortality in Elderly Patients with Clinically Localized Prostate Cancer Treated with Modern Radiotherapy: Is There a Negative Impact?Journal of clinical medicine · 2019Article
- Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.World journal of urology · 2019Article
- Multi-disciplinary and shared decision-making approach in the management of organ-confined prostate cancer.Arab journal of urology · 2018Review
- Radiothrerapy for Elderly Patients Aged ≥75 Years with Clinically Localized Prostate Cancer-Is There a Role of Brachytherapy?Journal of clinical medicine · 2018Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe evaluated the influence of age and comorbidity (Charlson score assessment) on localized prostate cancer therapeutic management and the risk of prostate cancer over- and under-treatment.
methodsAmong the 2571 prostate cancer cases diagnosed in 2011, a subset of 633 patients was randomly selected from the prospectively accrued cohort of the Regional Cancer Registry, among the 17 participating institutions. Treatment distributions were examined for patients at each individual prostate cancer risk, age and comorbidity level and analyzed by multivariate logistic regression analysis.
resultsTreatments with curative intent were observed less often when age increased (p < 0.001). We found no impact of the Charlson score on the selection of a curative treatment [HR 0.89, 95 % CI (0.70-1.15)]. A 20 % overtreatment rate was reported in low-risk prostate cancer patients. For younger patients (65-75 years) with high comorbidity score, a 14 % overtreatment rate was observed. Conversely, a 16 % undertreatment rate was reported in older patients >75 years without any significant comorbidity.
conclusionA better consideration of comorbidities could significantly reduce overtreatment in patients <75 year and promote curative treatment in aggressive prostate cancer for older patients without any significant comorbidity.
Indexed as
Identifiers
27443847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.